Results 31 to 40 of about 143,360 (302)

Secondary prevention of coronary heart disease in older patients after the national service framework: population based study [PDF]

, 2006
Objective To examine the extent of uptake of medication for secondary prevention of coronary heart disease in older British men and women before (1998-2001) and after (2003) the implementation of the national service framework.Design Two population based,
Morris, RW, Whincup, Peter H, Whincup, PH, Morris, Richard W, Papacosta, O, Ramsay, Sheena E, Ebrahim, S, Lawlor, Debbie A, Thomas, Mary C, Thomas, MC, Lennon, Lucy T, Lawlor, DA, Ramsay, SE, Lennon, LT, Ebrahim, Shah, Papacosta, Olia   +15 more
core   +1 more source

An assessment of quality of life among stroke survivors at tertiary care teaching hospital in South India: A randomized clinical trial

Precision Medical Sciences, 2023
The study's primary aim was to examine how a stroke affects health‐related quality of life (QoL), and a secondary aim was to link this event with clinical and sociodemographic factors. Stroke patients were included in the study.
Priya Mary, Srinivasan Sivannan, Karthikeyan Elumalai, Helan Williams, Vijayan Abhilash, Sivaneswari Srinivasan, Binoy Varghese Cheriyan, Mahalakshmi Devaraji   +7 more
doaj   +1 more source

Guideline-Directed Medical Therapy in the Management of Cardiovascular Disease: A Cross-sectional Questionnaire-based Study amongst Indian Healthcare Professionals [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Guideline-Directed Medical Therapies (GDMT) are evidence-based treatments recommended by clinical practice guidelines for the management of Cardiovascular Diseases (CVDs).
Prafulla Kerkar, Rajeev Garg, Abhishek Shukla, Viveka Kumar, Akshyaya Pradhan, Arindam Pande, Johan Christopher, Febin Francis, Nitin Zalte, Amarnath Sugumaran   +9 more
doaj   +1 more source

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

Platelets, 2022
BMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) antagonist exhibiting robust antithrombotic activity that has shown low bleeding risk in monkeys.
Samira Merali, Zhaoqing Wang, Charles Frost, Mario Callejo, Michael Hedrick, Lester Hui, Stephanie Meadows Shropshire, Ke Xu, Michel Bouvier, Mary M. DeSouza, Jing Yang   +10 more
doaj   +1 more source

Recurrent Stent Thrombosis Following Myocardial Infarction Associated With VITT-Like Antibodies

JACC: Case Reports
Early stent thrombosis is a rare complication of percutaneous intervention and is associated with significant 30-day mortality. We present a novel case of multiple recurrent early stent thrombosis consistent with spontaneous vaccine-induced thrombotic ...
Zulqarnain Khan, MD, Imari Patel, MD, Tiffany Gardner, PharmD, Xin Wei, MD, Michael Cheng, MD, Mark R. Vesely, MD, Roberto M. Benitez, MD, Ann B. Zimrin, MD, Libin Wang, MD, Aloke V. Finn, MD   +9 more
doaj   +1 more source

Ischemic Stroke From Libman-Sacks Endocarditis Not Associated With Antiphospholipid Antibodies

JACC: Case Reports, 2019
Libman-Sacks endocarditis (LSE), a cardiac complication of systemic lupus erythematosus, is commonly treated with anticoagulation for stroke prevention. We describe a patient with multifocal strokes secondary to LSE, treated with aspirin, without further
Michal Krawczyk, MD, MSc, Adrian Budhram, MD, Luciano A. Sposato, MD, MBA   +2 more
doaj   +1 more source

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

Platelets, 2023
BMS-986141 is a novel, oral, protease-activated, receptor 4 (PAR4)-antagonist that exhibited robust antithrombotic activity and low bleeding risk in preclinical studies.
Samira Merali, Zhaoqing Wang, Charles Frost, Stephanie Meadows-Shropshire, Dara Hawthorne, Jing Yang, Dietmar Seiffert   +6 more
doaj   +1 more source

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)

, 2013
The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy ...
TEBALDI, Matteo, Marco Valgimigli, Pascal Vranckx, for the PROlonging Dual antiplatelet treatment after Grading stent induced Intimal hyperplasia studY Investigators, BORGHESI, Marco, FERRARI, Roberto, Giovanni Parrinello   +6 more
core   +1 more source

Interaction of Intraprocedural Antiplatelets and Intravenous Thrombolysis in Acute Intracranial Stenting: RESISTANT Registry Subanalysis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction/Objective Acute intracranial stenting during endovascular thrombectomy (EVT) for ischemic stroke requires intraprocedural antiplatelet therapy (APT) to maintain patency. However, the hemorrhagic risk of combining APT with intravenous thrombolysis (IVT) remains uncertain.
Aaron Rodriguez‐Calienes, Leonardo Cruz‐Criollo, Eric Kontowicz, Marta Olivé‐Gadea, Francesco Diana, Johannes Kaesmacher, Adnan Mujanovic, Serdar Geyik, Songul Senadim, Amedeo Cervo, Andrea Salcuni, Mariangela Piano, Manuel Moreu, Alfonso López‐Frías, Ameer E. Hassan, Samantha Miller, Elena Zapata‐Arriaza, Asier de Albóniga‐Chindurza, Mauro Bergui, Stefano Molinaro, João André Sousa, Fábio Gomes, João Sargento‐Freitas, Andrea Alexandre, Alessandro Pedicelli, Jeremy Hofmeister, Paolo Machi, Luca Scarcia, Erwah Kalsoum, Jose Amorim, Torcato Meira, Leonardo Renieri, Francesco Capasso, Daniele Romano, Eduardo Bárcena‐Ruiz, David Seoane, Mohamad Abdalkader, Piers Klein, Thanh N. Nguyen, Catarina Perry da Câmara, Anderson Brito, Nashwa Abdelhakim, Isabel Fragata, Dileep R. Yavagal, Jude H. Charles, Jose Rodriguez Castro, Pedro Vega, Atilla Özcan Özdemir, Zehra Uysal Kocabaş, Stanislas Smajda, Sadiq Al Salman, Jane Khalife, Tudor G. Jovin, Francesco Biraschi, Francesca Richetti, Pedro Castro, Luis Albuquerque, Adnan Siddiqui, Vinay Jaikumar, Pedro Navia, Nikolaos Ntoulias, Marios Psychogios, Mariano Velo, Joaquín Zamarro, Gonzalo de Paco, Yazan Ashouri, Mohammad AlMajali, Juan F. Arenillas, Alicia Sierra, Michele Romoli, João Pedro Marto, Shadi Yaghi, Marc Ribo, Alejandro Tomasello, Manuel Requena, Santiago Ortega‐Gutierrez   +75 more
wiley   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source